Background: Prasugrel is a novel third-generation thienopyridine P2Y12 receptor antagonist with more rapid, potent, and consistent platelet inhibition than clopidogrel. [23] Aim: Compare the ...
For decades, aspirin has been the standard preventive treatment for patients with blood vessel disease. After an acute ...
P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback